Teva Pharmaceutical Industries, Ltd.: Migraine Disorders trials
The registry lists 20 Migraine Disorders studies with Teva Pharmaceutical Industries, Ltd. as lead sponsor. 1 are open to participants now and 15 have results posted.
Phase 1 3Phase 2 3Phase 3 12Phase 4 1No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Fremanezumab Managed Access Program for Pediatric PatientsAvailableNCT03539393
- A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With MigraineCompletedNCT05458011Phase 3Results posted
- A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and AdolescentsCompletedNCT04530110Phase 3Results posted
- A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Participants 6 to 17 Years of AgeCompletedNCT04464707Phase 3Results posted
- A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of AgeCompletedNCT04458857Phase 3Results posted
- A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive DisorderCompletedNCT04041284Phase 4Results posted
- An Efficacy and Safety Study of Fremanezumab in Adults With MigraineCompletedNCT03308968Phase 3Results posted
- Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of MigraineCompletedNCT02638103Phase 3Results posted
- Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic MigraineCompletedNCT02629861Phase 3Results posted
- Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic MigraineCompletedNCT02621931Phase 3Results posted
- A Multicenter Assessment of LBR-101 in High Frequency Episodic MigraineCompletedNCT02025556Phase 2Results posted
- Assessment of LBR-101 In Chronic MigraineCompletedNCT02021773Phase 2Results posted
- An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve MonthsCompletedNCT00806546Phase 3Results posted
- An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 MonthsCompletedNCT00792103Phase 3Results posted
- A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine HeadachesCompletedNCT00781456Phase 2Results posted
- The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute MigraineCompletedNCT00724815Phase 3Results posted
- Safety, Pharmacokinetic, and Tolerability Study of Zecuity® in Adolescent Subjects With a History of Acute MigraineCompletedNCT02684409Phase 1
- Phase I, Open Label, Single-Dose, Four Way Crossover Study to Compare the PK of NP101 With Oral Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine PeriodCompletedNCT00723983Phase 1
- Phase I Open Label Single-Dose Study to Compare the Pharmacokinetics of NP101 Healthy VolunteersCompletedNCT00720018Phase 1
- Evaluating the Safety and Tolerability of OraVescent Fentanyl for Opioid Tolerant Patients With Noncancer Related Breakthrough PainCompletedNCT00228605Phase 3